Corey Goodman is a scientist, educator, and entrepreneur. Corey has been a member of CCST since
2007, and was appointed Council Chair in 2014.
With a B.S. from Stanford University and Ph.D. from U.C. Berkeley, he spent 25 years as Professor of
Biology at Stanford University and Evan Rauch Chair of Neurobiology at Berkeley (Dept. of Molecular
and Cell Biology), where he was Howard Hughes Medical Institute Investigator, Head of the
Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. He published
over 200 peer-reviewed papers. He is currently an Adjunct Professor of Anatomy and Biochemistry &
Biophysics at U.C. San Francisco.
Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and
Sciences, and American Philosophical Society, and recipient of many honors including the Alan T.
Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology,
Reeve-Irvine Research Medal, and Dawson Prize in Genetics from Trinity College Dublin.
Dr. Goodman moved into biotechnology to help apply biomedical discoveries to human health. He has
co-founded six biotechnology companies, and led one of them as President and CEO from a private to
public company until its acquisition. He was recruited as President and founder of Pfizer's
Biotherapeutics and Bioinnovation Center and a member of Pfizer's executive leadership team.
Today Dr. Goodman is a Managing Partner of venBio Partners LLC, a strategic capital firm investing
in innovative therapeutics for major unmet medical needs, based on a model of strategic investment
with Amgen, Baxter, and PPD.
Dr. Goodman is currently Chair of the Board of Second Genome, Oligasis, Ossianix, Labrys Biologics,
Solstice Biologics, and Heart Metabolics. He is a member of the Board of Mirna.
Amongst his other public policy roles, Dr. Goodman is a member of the board of the Pacific
Institute, former Chair of the National Research Council's Board on Life Sciences, and past
President of the McKnight Endowment Fund for Neuroscience. He is an advisor to numerous biomedical